Narcan Disease Interactions

Therapy with naloxone in patients with preexisting cardiovascular disorders should be closely monitored for hypotension, hypertension, ventricular tachycardia or fibrillation, and pulmonary edema in an appropriate healthcare setting. Clinical monitoring of cardiovascular status is recommended.

The safety and effectiveness of naloxone injection in patients with liver disease have not been established. Caution should be exercised when naloxone is administered to patients with liver disease.

The safety and effectiveness of naloxone injection in patients with renal insufficiency/failure have not been established. Caution should be exercised when naloxone is administered to these patients.

Naloxone has been shown in some cases of septic shock to produce a rise in blood pressure that may last up to several hours; however, this pressor response has not been demonstrated to improve patient survival. In some studies, treatment with naloxone in the setting of septic shock has been associated with adverse effects, including agitation, nausea and vomiting, pulmonary edema, hypotension, cardiac arrhythmias, and seizures. The decision to use naloxone in septic shock should be exercised with caution, particularly in patients who may have underlying pain or have previously received opioid therapy and may have developed opioid tolerance.